rs1553135172
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_000302.4(PLOD1):c.965T>A(p.Ile322Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000616 in 1,461,852 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_000302.4 missense
Scores
Clinical Significance
Conservation
Publications
- Ehlers-Danlos syndrome, kyphoscoliotic type 1Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000302.4. You can select a different transcript below to see updated ACMG assignments.
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PLOD1 | TSL:1 MANE Select | c.965T>A | p.Ile322Asn | missense | Exon 9 of 19 | ENSP00000196061.4 | Q02809-1 | ||
| PLOD1 | c.1109T>A | p.Ile370Asn | missense | Exon 10 of 20 | ENSP00000524078.1 | ||||
| PLOD1 | c.1052T>A | p.Ile351Asn | missense | Exon 10 of 20 | ENSP00000524090.1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251302 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461852Hom.: 0 Cov.: 33 AF XY: 0.00000963 AC XY: 7AN XY: 727236 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 31
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.